New Assay System Elecsys Anti-p53 to Detect Serum Anti-p53 Antibodies in Esophageal Cancer Patients and Colorectal Cance
- PDF / 625,776 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 91 Downloads / 174 Views
ORIGINAL ARTICLE – TRANSLATIONAL RESEARCH
New Assay System Elecsys Anti-p53 to Detect Serum Anti-p53 Antibodies in Esophageal Cancer Patients and Colorectal Cancer Patients: Multi-institutional Study Satoshi Yajima, MD1, Takashi Suzuki, MD1, Yoko Oshima, MD1, Fumiaki Shiratori, MD1, Kimihiko Funahashi, MD1, Shinichi Kawai, MD2, Toshihiro Nanki, MD3, Sei Muraoka, MD3, Yoshihisa Urita, MD4, Yoshihisa Saida, MD5, Shinichi Okazumi, MD6, Yuko Kitagawa, MD7, Yuki Hirata, MD7, Hirotoshi Hasegawa, MD7, Koji Okabayashi, MD7, Masahiko Murakami, MD8, Takeshi Yamashita, MD8, Rei Kato, MD8, Hisahiro Matsubara, MD9, Kentaro Murakami, MD9, Yasuaki Nakajima, MD10, Hironobu Sugita, MSc11, Martin Klammer, PhD12, and Hideaki Shimada, MD1,13 1
Department of Surgery, School of Medicine, Toho University, Tokyo, Japan; 2Department of Inflammation and Pain Control Research, School of Medicine, Toho University, Tokyo, Japan; 3Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University, Tokyo, Japan; 4General Medicine and Emergency Center, School of Medicine, Toho University, Tokyo, Japan; 5Department of Surgery, Ohashi Medical Center, Toho University, Tokyo, Japan; 6Department of Surgery, Sakura Medical Center, Toho University, Tokyo, Japan; 7Department of General and Gastroenterological Surgery, Keio University Hospital, Tokyo, Japan; 8Department of Surgery, Showa University Hospital, Tokyo, Japan; 9Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan; 10 Esophageal Surgery, Medical Hospital, Tokyo Medical and Dental University, Tokyo, Japan; 11Roche Diagnostics K.K, Tokyo, Japan; 12Department of Biostatistics and Advanced Data Analytics, Roche Diagnostics GmbH, Penzberg, Germany; 13Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan
ABSTRACT Background. Several recent studies suggest that serum anti-p53 antibodies (s-p53-Abs) may be combined with other markers to detect esophageal and colorectal cancer. In this study, we assessed the sensitivity and specificity of s-p53-Abs detection of a new electrochemiluminescence immunoassay (ECLIA; Elecsys anti-p53). Methods. Elecsys anti-p53 assay was used to analyze the level of s-p53-Abs in blood sera from patients with esophageal or colorectal cancer taken before treatment. Control blood sera from healthy volunteers, patients with benign diseases, and patients with autoimmune diseases served as a reference. In addition, squamous cell carcinoma
Ó Society of Surgical Oncology 2020 First Received: 31 August 2020 Accepted: 20 October 2020 H. Shimada, MD e-mail: [email protected]
antigen (SCC-Ag) and cytokeratin 19 fragments (CYFRA21-1) were assessed in patients with esophageal cancer, and carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 were assessed in patients with colorectal cancer. Results. Samples from 281 patients with esophageal cancer, 232 patients with colorectal cancer, and 532 controls were included in the st
Data Loading...
